Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus
Liver International · 2024
DOI: 10.1111/liv.15845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Natália Coelho Lavrado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Post Graduate Program, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/Aims Longitudinal studies assessing the impact of genetic polymorphisms on outcomes in patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) are scarce. This study aimed to evaluate the effect of PNPLA3 and TM6SF2 risk alleles on hepatic and extrahepatic outcomes in T2DM‐MASLD individuals.
Methods
Patients' polymorphisms were analysed as follows: PNPLA3 CC, CG and GG; TM6SF2 CC and CT + TT; combined comparing no mutant allele, one allele G or T or ≥2 alleles G or T. Hierarchical models were built to assess associations between polymorphisms and outcomes, independently of confounding factors. Multivariate logistic regression was used for cirrhosis and its complications and extrahepatic cancer, and Cox regression for cardiovascular events (CVEs) and all‐cause mortality.
Results
In total, 407 T2DM‐MASLD patients (62.1 ± 10.5 years, 67.6% women) were followed for 11 (6–13) years. Having at least one G or T allele independently increased the risk of cirrhosis in the separate analysis of PNPLA3 and TM6SF2. Combined polymorphism analysis demonstrated an even higher risk of cirrhosis if two or more risk alleles were present (OR 18.48; 95% CI 6.15–55.58; p < .001). Regarding cirrhosis complications, the risk was higher in PNPLA3 GG and TM6SF2 CT + TT, also with an even higher risk when two or more risk alleles were present in the combined evaluation (OR 27.20; 95% CI 5.26–140.62; p < .001). There were no associations with CVEs or mortality outcomes.
Conclusion
In T2DM, PNPLA3 and TM6SF2 polymorphisms, individually and additively, impact MASLD severity, with an increased risk of cirrhosis and its complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Post Graduate Program, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Internal Medicine, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Laboratory of Molecular Biology, Medicine Department, University of Joinville Region - UNIVILLE, Joinville, Brazil.
- Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Division of Hepatology, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Natália Coelho Lavrado, Gil Fernando Salles, Claudia Regina Lopes Cardoso, Paulo Henrique Condeixa de França, Maria Fernanda Di Guimarães Gonçalves Melo, Nathalie Carvalho Leite, Cristiane Alves Villela-Nogueira
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES)
Zitieren
APA
Lavrado, N. C., Salles, G. F., Cardoso, C. R. L., de França, P. H. C., Melo, M. F. D. G. G., Leite, N. C., & Villela-Nogueira, C. A. (2024). Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus. Liver International. https://doi.org/10.1111/liv.15845
Vancouver
Lavrado NC, Salles GF, Cardoso CRL, de França PHC, Melo MFDGG, Leite NC, et al. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus. Liver International. 2024. doi:10.1111/liv.15845
BibTeX
@article{Lavrado2024,
author = {Lavrado, Natália Coelho and Salles, Gil Fernando and Cardoso, Claudia Regina Lopes and de França, Paulo Henrique Condeixa and Melo, Maria Fernanda Di Guimarães Gonçalves and Leite, Nathalie Carvalho and Villela-Nogueira, Cristiane Alves},
title = {Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15845}
}
EUVIMED